首剂量需要加倍或减量的心血管药物,了解一下

2018-08-13 佚名 沈阳202医院药剂科微信号

临床常用的心血管药物中,很多需要首剂加倍或减量。我们一起了解一下。

临床常用的血管药物中,很多需要首剂加倍或减量。我们一起了解一下。

首剂加倍

临床用药过程中,为了迅速使血药浓度达到稳态浓度,即坪值,使得药物迅速产生效应,常常采用首剂加倍的方法,即:第一次服药时,用药量要加倍,后续剂量仍按照常规剂量使用,以保证临床用药的安全性。目的是使药物在一个半衰期内迅速达到稳态浓度,缩短药物达到有效浓度的时间,立即发挥治疗作用,迅速缓解病情。

首剂加倍是基于每种药物的药动学过程,经过大量科学研究证明、探索,结合药效学及药物安全性等诸多因素制定出的负荷剂量给药方案。“首剂加倍”的多为抗微生物药物,例如阿奇霉素、替考拉宁、甲硝唑等;部分止泻药用于治疗急性腹泻时也需要首剂加倍。

药物举例

01.阿司匹林

拜阿司匹林说明书:降低急性心肌梗死疑似患者的发病风险,建议首次剂量300mg,嚼碎后服用以快速吸收,以后每天100-200mg。

《急性ST段抬高型心肌梗死诊断和治疗指南(2015)》:所有无禁忌证的STEMI患者均应立即口服水溶性阿司匹林或嚼服肠溶阿司匹林300 mg(Ⅰ,B),继以75~100 mg/d长期维持(Ⅰ,A)。

《非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016)》:阿司匹林是抗血小板治疗的基石,如无禁忌证,无论采用何种治疗策略,所有患者均应口服阿司匹林首剂负荷量150~300mg(未服用过阿司匹林的患者)并以75~100mg/d的剂量长期服用(I,A)。

02.P2Y12受体抑制剂

氯吡格雷(波立维)说明书:非ST段抬高型急性冠脉综合征患者,应以单次负荷量氯吡格雷300mg开始,然后以75mg,每日1次连续服药(合用阿司匹林75-325mg/日)。ST段抬高型急性心肌梗死:应以负荷量氯吡格雷开始,然后以75mg每日1次,合用阿司匹林,可合用或不合用溶栓剂。对于年龄超过75岁的患者,不使用氯吡格雷负荷剂量。

替格瑞洛(倍林达)说明书:本品起始剂量为单次负荷量180 mg(90 mg×2片),此后每次1片(90 mg),每日2次。

《急性ST段抬高型心肌梗死诊断和治疗指南(2015)》:STEMI直接PCI(特别是置入DES)患者,应给予负荷量替格瑞洛180 mg,以后90 mg/次,每日2次,至少12个月(Ⅰ,B);或氯吡格雷600 mg负荷量,以后75 mg/次,每日1次,至少12个月(Ⅰ,A)。STEMI静脉溶栓患者,如年龄≤75岁,应给予氯吡格雷300 mg负荷量,以后75 mg/d,维持12个月(Ⅰ,A)。如年龄>75岁,则用氯吡格雷75 mg,以后75 mg/d,维持12个月(Ⅰ,A)。STEMI合并房颤需持续抗凝治疗的直接PCI患者,建议应用氯吡格雷600 mg负荷量,以后每天75 mg(Ⅱa,B)。

《非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016)》:除非有极高出血风险等禁忌证,在阿司匹林基础上应联合应用1种P2Y12受体抑制剂,并维持至少12个月(I,A)。选择包括替格瑞洛(180mg负荷剂量,90mg、2次/d维持)或氯吡格雷(负荷剂量300~600mg,75mg/d维持)(I,B)。

首剂减量

有些药物作用较强烈,首剂药物如按常规剂量给予,容易导致患者不耐受,即首剂效应或首剂综合征。为避免首剂效应的发生,对某些药物须采取“首剂减量”法。引起首剂效应的常见药物主要是抗高血压药物、冠心病和心力衰竭治疗药物等。

药物举例

01.α受体阻滞剂——哌唑嗪

口服,一次0.5mg~1mg,每日2~3次(首剂为0.5mg,睡前服)。逐渐按疗效调整为一日6mg~15mg,分2~3次服,每日剂量超过20mg后,疗效不进一步增加。

本品可引起晕厥,大多数由体位性低血压引起,偶发生在心室率为100~160次/分的情况下,通常在首次给药后30~90分钟或与其他降压药合用时出现。低钠饮食与合用β受体阻滞剂的患者较易发生。如果将首次剂量改为0.5mg,临睡前服用,可防止或减轻这种不良反应;在给本药前一天停止使用利尿药,也可减轻“首剂现象”。这种副作用有自限性,多数情况下不会再发生。眩晕和嗜睡可发生在首次服药后,在首次服药或加量后第一日应避免驾车和危险的工作。目眩可发生于体位由卧位变为立位时,缓慢起床可避免。

02.钙拮抗剂——硝苯地平

剂量应视患者的耐受性和对心绞痛的控制情况逐渐调整。过量服用硝苯地平可导致低血压。建议从小剂量开始服用,一般首剂用量10mg/次,一日3次口服。通常调整剂量需7-14天。

03.血管紧张素转换酶抑制剂——依那普利

原发性高血压:根据高血压的严重程度,起始剂量为10-20 mg,每日1次。对轻度高血压,建议起始剂量为每日10 mg。治疗其他程度的高血压,起始剂量为每日20 mg。常用维持量为20 mg/日,根据病人的需要,可调整至最大剂量每日40 mg。

心衰/无症状性左心室功能不全:有症状的心衰或无症状的左心室功能不全病人,起始剂量为2.5 mg,并应在密切的医疗监护下服用,以确定其对血压的起始效应。如果没有发生症状性低血压或症状性低血压已得到有效的处理,应根据病人的耐受情况将剂量逐渐增加到常用的20 mg维持剂量,1次或分2次服用。这一剂量调整可经过2-4周的时间完成。若仍存在部分的心衰体征和症状,剂量递增过程还可以加快。

04.血管紧张素II受体阻滞剂——厄贝沙坦

通常建议的初始剂量和维持剂量为每日150 mg,饮食对服药无影响。但对某些特殊的病人,特别是进行IBD%E8%AF%8A%E6%B2%BB%E8%BF%87%E7%A8%8B%E4%B8%AD%E7%9A%84%E8%AF%84%E4%BC%B0-Part%202" target="_blank">血液透析和年龄超过75岁的病人,初始剂量可考虑用75 mg。使用厄贝沙坦150 mg每天一次不能有效控制血压的患者,可将本品剂量增至300 mg,或者增加其它抗高血压药物。

05.β受体阻滞剂——美托洛尔

心绞痛开始一次25-50mg,一日2-4次;以一周为间隔逐渐加量直到达到目标剂量;最大日剂量400mg,分3次服。

心力衰竭应在使用洋地黄和/或利尿剂等抗心衰的治疗基础上使用本药;起初一次6.25mg,一日2~3次,以后视临床情况每数日至一周一次增加6.25-12.5mg,一日2~3次,最大剂量可用至一次50~100mg,一日2次。

06.阿托伐他汀

适应证包括高胆固醇血症和冠心病。常用的起始剂量为10mg每日一次。剂量调整时间间隔应为4周或更长。最大剂量为80mg每日一次。

07.瑞舒伐他汀

适应证包括原发性高胆固醇血症、混合型血脂异常、纯合子家族性高胆固醇血症等。常用起始剂量为5 mg,每日一次;需要更强效地降低低密度脂蛋白胆固醇(LDL-C)的患者可以考虑10mg一日一次作为起始剂量,该剂量能控制大多数患者的血脂水平。如有必要,可在治疗4周后调整剂量至高一级的剂量水平。每日最大剂量为20mg。

首剂加减使用需谨慎!

首剂加减有必要,但并非每种药都应首剂加倍或减量,应用必须谨慎。

1.在众多药物中只有少数药才能首剂加倍,不加选择地首剂加倍,反而有可能造成病人中毒。

2.首剂加倍并非适合所有人,对于老人、年幼者等特殊人群或者肝肾功能衰退患者,首剂加倍服用反而会对机体造成损害。

3.需根据病种决定是否需要首剂加倍。

4.药物治疗窗窄的药物首剂加倍必须谨慎,监测血药浓度,以免出现中毒。比如地高辛的治疗窗窄,血清有效浓度为0.8~2.0ng/ml,大于2.0~2.5ng/ml时应警惕药物过量或中毒反应。

5.有的药物首剂效应的发生率与用药的剂量有关,开始用药的剂量越大,首剂效应的发生率越高。因此,对于具有这种性质的药物,其用量应从小剂量开始,根据病情和耐受情况逐渐加大到一般治疗剂量较为安全。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1646040, encodeId=891d16460407c, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Sun Feb 24 22:07:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338302, encodeId=6832338302e6, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Aug 13 08:51:12 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338285, encodeId=966e338285f1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Mon Aug 13 07:43:37 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338281, encodeId=458233828163, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Aug 13 07:35:57 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338269, encodeId=118c33826910, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Mon Aug 13 07:17:35 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338264, encodeId=80bd33826498, content=学习了,谢谢分享,比较实用~, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Mon Aug 13 07:04:06 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338258, encodeId=1dd7338258bb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Mon Aug 13 06:55:42 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338248, encodeId=380733824886, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Aug 13 06:52:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338237, encodeId=071533823e1c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Aug 13 05:57:55 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1646040, encodeId=891d16460407c, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Sun Feb 24 22:07:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338302, encodeId=6832338302e6, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Aug 13 08:51:12 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338285, encodeId=966e338285f1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Mon Aug 13 07:43:37 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338281, encodeId=458233828163, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Aug 13 07:35:57 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338269, encodeId=118c33826910, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Mon Aug 13 07:17:35 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338264, encodeId=80bd33826498, content=学习了,谢谢分享,比较实用~, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Mon Aug 13 07:04:06 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338258, encodeId=1dd7338258bb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Mon Aug 13 06:55:42 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338248, encodeId=380733824886, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Aug 13 06:52:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338237, encodeId=071533823e1c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Aug 13 05:57:55 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1646040, encodeId=891d16460407c, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Sun Feb 24 22:07:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338302, encodeId=6832338302e6, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Aug 13 08:51:12 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338285, encodeId=966e338285f1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Mon Aug 13 07:43:37 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338281, encodeId=458233828163, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Aug 13 07:35:57 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338269, encodeId=118c33826910, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Mon Aug 13 07:17:35 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338264, encodeId=80bd33826498, content=学习了,谢谢分享,比较实用~, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Mon Aug 13 07:04:06 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338258, encodeId=1dd7338258bb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Mon Aug 13 06:55:42 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338248, encodeId=380733824886, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Aug 13 06:52:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338237, encodeId=071533823e1c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Aug 13 05:57:55 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2018-08-13 衣带渐宽

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1646040, encodeId=891d16460407c, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Sun Feb 24 22:07:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338302, encodeId=6832338302e6, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Aug 13 08:51:12 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338285, encodeId=966e338285f1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Mon Aug 13 07:43:37 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338281, encodeId=458233828163, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Aug 13 07:35:57 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338269, encodeId=118c33826910, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Mon Aug 13 07:17:35 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338264, encodeId=80bd33826498, content=学习了,谢谢分享,比较实用~, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Mon Aug 13 07:04:06 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338258, encodeId=1dd7338258bb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Mon Aug 13 06:55:42 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338248, encodeId=380733824886, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Aug 13 06:52:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338237, encodeId=071533823e1c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Aug 13 05:57:55 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2018-08-13 phoebeyan520

    学习了,谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1646040, encodeId=891d16460407c, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Sun Feb 24 22:07:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338302, encodeId=6832338302e6, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Aug 13 08:51:12 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338285, encodeId=966e338285f1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Mon Aug 13 07:43:37 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338281, encodeId=458233828163, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Aug 13 07:35:57 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338269, encodeId=118c33826910, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Mon Aug 13 07:17:35 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338264, encodeId=80bd33826498, content=学习了,谢谢分享,比较实用~, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Mon Aug 13 07:04:06 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338258, encodeId=1dd7338258bb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Mon Aug 13 06:55:42 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338248, encodeId=380733824886, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Aug 13 06:52:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338237, encodeId=071533823e1c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Aug 13 05:57:55 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2018-08-13 执着追梦

    学习,谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1646040, encodeId=891d16460407c, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Sun Feb 24 22:07:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338302, encodeId=6832338302e6, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Aug 13 08:51:12 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338285, encodeId=966e338285f1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Mon Aug 13 07:43:37 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338281, encodeId=458233828163, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Aug 13 07:35:57 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338269, encodeId=118c33826910, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Mon Aug 13 07:17:35 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338264, encodeId=80bd33826498, content=学习了,谢谢分享,比较实用~, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Mon Aug 13 07:04:06 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338258, encodeId=1dd7338258bb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Mon Aug 13 06:55:42 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338248, encodeId=380733824886, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Aug 13 06:52:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338237, encodeId=071533823e1c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Aug 13 05:57:55 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2018-08-13 太阳系小猪

    学习了,谢谢分享,比较实用~

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1646040, encodeId=891d16460407c, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Sun Feb 24 22:07:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338302, encodeId=6832338302e6, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Aug 13 08:51:12 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338285, encodeId=966e338285f1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Mon Aug 13 07:43:37 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338281, encodeId=458233828163, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Aug 13 07:35:57 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338269, encodeId=118c33826910, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Mon Aug 13 07:17:35 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338264, encodeId=80bd33826498, content=学习了,谢谢分享,比较实用~, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Mon Aug 13 07:04:06 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338258, encodeId=1dd7338258bb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Mon Aug 13 06:55:42 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338248, encodeId=380733824886, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Aug 13 06:52:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338237, encodeId=071533823e1c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Aug 13 05:57:55 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2018-08-13 哈哈869

    学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1646040, encodeId=891d16460407c, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Sun Feb 24 22:07:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338302, encodeId=6832338302e6, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Aug 13 08:51:12 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338285, encodeId=966e338285f1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Mon Aug 13 07:43:37 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338281, encodeId=458233828163, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Aug 13 07:35:57 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338269, encodeId=118c33826910, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Mon Aug 13 07:17:35 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338264, encodeId=80bd33826498, content=学习了,谢谢分享,比较实用~, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Mon Aug 13 07:04:06 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338258, encodeId=1dd7338258bb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Mon Aug 13 06:55:42 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338248, encodeId=380733824886, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Aug 13 06:52:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338237, encodeId=071533823e1c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Aug 13 05:57:55 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2018-08-13 sunfeifeiyang

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1646040, encodeId=891d16460407c, content=<a href='/topic/show?id=470051898b0' target=_blank style='color:#2F92EE;'>#心血管药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51898, encryptionId=470051898b0, topicName=心血管药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b223291988, createdName=jiafufeng@yaho, createdTime=Sun Feb 24 22:07:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338302, encodeId=6832338302e6, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Mon Aug 13 08:51:12 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338285, encodeId=966e338285f1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Mon Aug 13 07:43:37 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338281, encodeId=458233828163, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Aug 13 07:35:57 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338269, encodeId=118c33826910, content=学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Mon Aug 13 07:17:35 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338264, encodeId=80bd33826498, content=学习了,谢谢分享,比较实用~, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Mon Aug 13 07:04:06 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338258, encodeId=1dd7338258bb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Mon Aug 13 06:55:42 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338248, encodeId=380733824886, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Aug 13 06:52:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338237, encodeId=071533823e1c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Aug 13 05:57:55 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2018-08-13 青山颖钰

    学习了

    0

相关资讯

Circulation:美国心脏协会提出改善心血管药物可及性的八项原则

发表在《Circulation》上的一项综述,对美国在药物上花费不断增加的原因进行了阐述,旨在为美国心脏协会在致力于改善所有美国人心血管健康这一目标上提供一些帮助。

斯利康心血管药物Brilinta临床试验效果显著

近日一项临床试验表明,长期服用阿斯利康的Brilinta(替卡格雷)可以使具有心脏病或中风病史的患者的死亡率降低16%,这项研究可能会大幅增加这款药物的销量,对阿斯利康而言无疑是一利好消息,但对医生而言,开处方前要充分考虑该药物带来的风险和收益,尤其是该药物可能造成出血的风险。 波士顿布里翰妇女医院的研究人员Marc Sabatine表示,尽管Brilinta造成出血的风险增加,但是

杨丽教授:常用心血管药物安全性探讨

  杨丽教授 过去30年间,心脑血管疾病始终是我国城乡居民首位死因。国务院2015年6月发布的《中国居民营养与慢性病状况报告(2015)》显示,慢性疾病已成为影响居民健康的主要问题,2012年全国18岁及以上成人高血压患病率为25.2%,与2002年相比,患病率呈上升趋势。2012年全国居民慢性病死亡率为533/10万,占总死亡人数的86.6%,其中心脑血管病死亡率占首位

Hypertension:这种心血管药物影响肥胖高血压患者运动性脂质代谢吗?

脂肪酸慢性增加会促进心肌脂毒性、血脂异常、胰岛素抵抗和2型糖尿病。相反,降低脂肪酸水平的干预可改善代谢健康。这些观察结果与心血管药物影响脂代谢作用的潜力密切相关。2018年1月,发表在《Hypertension》的一项由德国、荷兰、瑞士和印度科学家进行的多中心、随机、双盲研究,考察了沙库巴曲/缬沙坦对肥胖高血压患者运动性脂质代谢的影响。

胡大一:心血管药物应使用“中国剂量”!

胺碘酮 我认真回忆了众多有关剂量的故事。1985-1987年在美国做访问学者时,我发现美国医生使用胺碘酮的负荷剂量为1200-1800mg/d,维持量为600-800mg/d,甲状腺功能异常与肺间质纤维化的严重不良反应引起人们的极大关注。回国后,看到黄宛教授使用胺碘酮的剂量远远小于美国剂量,他用的负荷剂量为600mg/d,维持量200mg/d,甚至更小。不但疗效好,而且不良反应明显小于美

Int J Cardiol:房颤患者抗高血压药物及相关心血管药物与痴呆风险

由此可见,处方中含有抗高血压药物,包括噻嗪类/RAAS阻滞剂联合治疗和华法林的使用,与痴呆发病率降低有关。